MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/cvr/cvae109

Медицинская библиотека · Cardiovascular research · 2024

Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial.

Wright R Scott, Raal Frederick J, Koenig Wolfgang, Landmesser Ulf, Leiter Lawrence A, Vikarunnessa Sheikh, Lesogor Anastasia, Maheux Pierre, Talloczy Zsolt, Zang Xiao, Schwartz Gregory G, Ray Kausik K

СтатьяМногоцентровое исследованиеКлиническое исследование III фазыКлиническое исследование II фазыРандомизированное исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

AIMS: Data describing the long-term efficacy and tolerability of inclisiran are limited. This was explored in ORION-8, an open-label extension of preceding Phase 2 and Phase 3 placebo-controlled and open-label extension trials.

METHODS AND

RESULTS

Following completion of the parent trial, adult patients with atherosclerotic cardiovascular disease (ASCVD), ASCVD risk equivalent, or heterozygous familial hypercholesterolaemia received open-label inclisiran twice yearly (after initial and 3-month doses) until Day 990, followed by an end-of-study visit at Day 1080 or ≥ 90 days after the last dose. The study endpoints included the proportion of patients achieving pre-specified low-density lipoprotein cholesterol (LDL-C) goals [ASCVD: < 1.8 mmol/L (< 70 mg/dL); ASCVD risk equivalent: < 2.6 mmol/L (< 100 mg/dL)], percentage and absolute changes in LDL-C at end-of-study, and safety of inclisiran. Of 3274 patients, 2446 (74.7%) were followed until end-of-study. Mean age was 64.9 ± 9.9 years, 82.7% (n = 2709) had ASCVD, and mean baseline LDL-C was 2.9 ± 1.2 mmol/L. Mean cumulative exposure to inclisiran (including parent trials) was 3.7 years; maximum exposure was 6.8 years. With inclisiran, 78.4% [95% confidence interval (CI): 76.8, 80.0] of patients achieved pre-specified LDL-C goals and mean percentage change in LDL-C was -49.4% (95% CI: -50.4, -48.3). No attenuation of LDL-C lowering over time was observed. Treatment-emergent adverse events at injection site (all mild/moderate) occurred in 5.9% of the patients. Inclisiran-associated anti-drug antibodies were infrequent (5.5%) and had no impact on the efficacy or safety of inclisiran. No new safety signals were identified.

CONCLUSION

In the largest and longest follow-up to date with >12 000 patient-years exposure, inclisiran demonstrated consistent and effective LDL-C lowering with a favourable long-term safety and tolerability profile.

TRIAL REGISTRATION NUMBER: ClinicalTrials.gov identifier: NCT03814187.

Для цитирования: Wright R Scott, Raal Frederick J, Koenig Wolfgang, Landmesser Ulf, Leiter Lawrence A, Vikarunnessa Sheikh, Lesogor Anastasia, Maheux Pierre, Talloczy Zsolt, Zang Xiao, Schwartz Gregory G, Ray Kausik K. Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial.. Cardiovascular research. 2024. DOI: 10.1093/cvr/cvae109.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.